AZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent.
More Information Supplier PageAZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent.
More Information Supplier PageAZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent.
More Information Supplier PageGSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.
More Information Supplier PageMK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
More Information Supplier PageLapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.
More Information Supplier PageLapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.
More Information Supplier PageLapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.
More Information Supplier PageLapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.
More Information Supplier PageLapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.
More Information Supplier Page
